Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liso-cel vs Standard of Care in R/R CLL/SLL
NCT06205290Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Primary completion
- Oct 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 11
01
Overview
A Phase 3 trial of lisocabtagene maraleucel in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Bristol Myers Squibb. Planned start Jan 2024; status: withdrawn.
02
Drugs
lisocabtagene maraleucel
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06205290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205290.